Search
Vaccines Treatment Options in Durham, NC
A collection of 49 research studies where Vaccines is the interventional treatment. These studies are located in the Durham, NC. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
1 - 12 of 49
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
07/24/2025
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina
Conditions: Avian Influenza
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
Completed
This is a pilot, prospective, randomized, open-label clinical trial. During the study, pregnant women will be randomized (1:1) to receive co-administration of a single intramuscular (IM) 0.5 mL dose of US-licensed inactivated influenza vaccine (IIV) and a single intramuscular (IM) 0.5 mL dose of US-licensed Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) or sequential administration of the vaccines (IIV followed by Tdap \~ 21 days later). Vaccines will b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/08/2025
Locations: Duke University, Durham, North Carolina
Conditions: Pregnancy
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
Active Not Recruiting
This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1).
Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, de... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Duke University, Durham, North Carolina +1 locations
Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Active Not Recruiting
The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (... Read More
Gender:
ALL
Ages:
Between 3 years and 35 years
Trial Updated:
07/04/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Active Not Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Velocity Clinical Research - Durham- Site Number : 8401175, Durham, North Carolina
Conditions: Dermatitis Atopic
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
Active Not Recruiting
This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19 vaccine and other vaccines at separate visits (Visits 1 and 2).
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
06/06/2025
Locations: Duke University, Durham, North Carolina
Conditions: Fever After Vaccination, Fever, Seizures Fever
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Cary Medical Group, Cary, North Carolina +9 locations
Conditions: SARS-CoV2, COVID-19
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Active Not Recruiting
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina
Conditions: Glioma, Malignant
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Recruiting
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine.
To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and... Read More
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
03/28/2025
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina +1 locations
Conditions: Pneumococcal Disease
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Terminated
The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.
Gender:
ALL
Ages:
Between 6 months and 25 months
Trial Updated:
02/19/2025
Locations: Duke Vaccine and Trials Unit CRS, Durham, North Carolina
Conditions: Respiratory Syncytial Virus (RSV)
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
Completed
The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are:
* safe; and
* how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign.
RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several differen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina +1 locations
Conditions: Influenza, Human
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Completed
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and ca... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/11/2024
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina +9 locations
Conditions: Influenza, COVID-19
1 - 12 of 49